Prelude
Australia is a key jurisdiction for life sciences and biotechnology patents and IP Australia has specific requirements for applications that disclose biological sequences. While these requirements align with WIPO Standard ST.26, they also include Australia-specific procedural and filing rules. Whether you’re filing a direct Australian application, a PCT national phase entry, or a standard patent, compliance with sequence listing requirements is essential. Non-compliant filings can trigger formal objections, examination delays, additional costs and administrative complications. This guide outlines IP Australia’s sequence listing requirements for 2026, covering the ST.26 framework, filing procedures, PCT national phase considerations, amendment rules and the most common compliance issues that lead to objections.
Legal Framework: Why Sequence Listings Are Required in Australia
The Patents Act 1990 and Patents Regulations 1991
Sequence listing requirements in Australia are grounded in the Patents Act 1990 (Cth) and the Patents Regulations 1991 (Cth). The regulations incorporate by reference the requirements of the Patent Cooperation Treaty and WIPO standards for sequence listings, making ST.26 compliance a direct regulatory requirement for PCT national phase entries.
For direct national filings (applications filed directly with IP Australia rather than entering through the PCT), the same ST.26 requirements apply. IP Australia formally adopted ST.26 on 1 July 2022, consistent with the international transition timeline.
The Incorporation of ST.26
WIPO Standard ST.26 defines the format and content requirements for sequence listings submitted with patent applications worldwide. IP Australia’s adoption of ST.26 means that:
- All new sequence listings filed with IP Australia must be in ST.26 XML format
- ST.25 plain-text format is no longer accepted for new filings as of 1 July 2022
- ST.25 listings submitted in applications with a filing date before 1 July 2022 may remain in ST.25 format for the life of that application, subject to IP Australia’s transitional provisions
- Conversion from ST.25 to ST.26 may be required in specific circumstances (discussed below)
Which Applications Require a Sequence Listing
A sequence listing is required in any Australian patent application – whether standard patent or PCT national phase entry – that discloses one or more nucleotide or amino acid sequences that:
- Are 10 or more residues in length
- Fall within the definition of a sequence under WIPO ST.26 (nucleotide sequences of deoxyribonucleotides or ribonucleotides; amino acid sequences of naturally occurring L-amino acids)
Short sequences of fewer than 10 residues do not require inclusion in a formal sequence listing but may still be recited in the specification.
Sequences disclosed only in drawings, without any textual description or claim reference, may fall outside the mandatory listing requirement – but this is a judgment call that should be confirmed with a qualified Australian patent attorney rather than assumed.
ST.26 Technical Requirements as Applied by IP Australia
File Format and Software
IP Australia requires sequence listings in ST.26-compliant XML format. The WIPO Sequence tool – the free, WIPO-developed software for creating ST.26 XML files – is the recommended and most commonly used preparation tool. IP Australia does not mandate use of WIPO Sequence specifically, but any alternative tool must produce fully ST.26-compliant XML output that passes validation.
WIPO Sequence is available free of charge at: www.wipo.int/standards/en/sequence
Always use the most current version. WIPO updates the software periodically to address validation bugs and incorporate regulatory changes.
ST.26 XML Structure: Key Requirements
A compliant ST.26 sequence listing for IP Australia must contain:
Applicant information The applicant name as it appears on the patent application. Consistency between the sequence listing and the application documents is mandatory – discrepancies generate formal deficiencies.
Invention title Copy verbatim from the patent application. Character-for-character consistency is required.
Application number and filing date For applications where these are known at the time of sequence listing preparation. For PCT applications entering national phase, the PCT international application number is used initially; the Australian national phase application number is added when it becomes available.
Software version Generated automatically by WIPO Sequence. Do not modify.
Sequence data Each sequence must be entered with:
- Correct sequence type (DNA, RNA, AA, or chimeric DNA/RNA)
- Accurate sequence length (calculated automatically by WIPO Sequence)
- Organism name in controlled vocabulary form – use the WIPO Sequence lookup function to confirm
- For synthetic sequences, “Artificial Sequence” designation with a mandatory /note qualifier explaining the nature of the synthetic sequence
- Mandatory feature annotations where required by ST.26 (see below)
Feature Annotation Requirements
ST.26 requires structured feature annotations for biologically significant elements within sequences. IP Australia applies the standard ST.26 annotation requirements without significant local variation, but several annotation points deserve emphasis for Australian filings:
CDS (coding sequence) features must be annotated with the /product qualifier naming the encoded protein. This is mandatory, not optional.
Signal peptides must be annotated with the sig_peptide feature key when present.
Antibody sequences – particularly relevant given Australia’s strong biologics patent activity – require annotation of variable regions (V_region), constant regions (C_region) and CDR regions. Incomplete annotation of monoclonal antibody sequences is one of the most common sources of examination objections in this technology area.
Modified residues – non-standard amino acids or chemically modified nucleotides – must be annotated using the appropriate feature keys and qualifiers. Failure to annotate modifications that are disclosed and claimed in the specification generates both formal and substantive objections.
Synthetic sequences require a /note qualifier that is more than a generic label. “Synthetic construct” alone is insufficient if the specification describes the function or design basis of the synthetic sequence – that information must be reflected in the annotation.
Validation Before Filing
Before submitting any sequence listing to IP Australia, validate the file using:
- The WIPO Sequence built-in validator – run through Tools → Validate within the WIPO Sequence application
- The standalone WIPO Sequence validator – available at the same download page as the main WIPO Sequence software; validates the exported XML file as a standalone document
- IP Australia’s own validation guidance – IP Australia publishes specific validation guidance in its patent filing documentation; confirm current requirements at ipaustralia.gov.au
A file that passes WIPO validation but fails IP Australia-specific checks is still a non-compliant filing. Run both validations before submission.
Filing Procedures: How to Submit a Sequence Listing to IP Australia
Electronic Filing Through eServices
IP Australia accepts patent applications and associated documents through its eServices portal at ipaustralia.gov.au. Electronic filing is the standard and strongly preferred method.
For the sequence listing:
- Upload the ST.26 XML file as a separate document component within the patent application package
- The file must be clearly identified as the sequence listing in the upload interface
- File naming should follow IP Australia’s guidance – check current naming conventions in the eServices help documentation, as these are updated periodically
IP Australia does not impose a specific file size limit for sequence listings in its published guidance, but very large sequence listings (typically those arising from genomic or metagenomic applications with thousands of sequences) should be discussed with IP Australia’s formalities team before filing to confirm the preferred submission approach.
Paper Filing (Exceptional Circumstances Only)
Paper filing of sequence listings is technically permitted but strongly discouraged by IP Australia. In practice, the complexity of ST.26 XML format makes paper filing effectively impossible for new applications – ST.26 is a machine-readable format and cannot be rendered meaningfully on paper. For any application requiring a sequence listing, electronic filing through eServices is the only practical approach.
Filing Fees
IP Australia charges standard patent filing fees that are not separately itemized by the presence of a sequence listing. However, if a sequence listing exceeds prescribed size thresholds, excess page or data fees may apply under the Patents Regulations. As fee schedules are updated annually, always verify current fees at ipaustralia.gov.au/patents/fees before filing.
PCT National Phase Entry: Sequence Listing Requirements
The majority of biotechnology patent applications filed in Australia enter through the PCT national phase rather than as direct national filings. The sequence listing requirements for PCT national phase entries have specific procedural nuances.
Timing of National Phase Entry
Australian national phase entry must be completed within 31 months of the earliest priority date – one month later than the standard 30-month PCT deadline. This 31-month deadline is one of Australia’s PCT-specific provisions and applies to both the substantive application and any associated documents, including the sequence listing.
Sequence Listing Status at National Phase Entry
When entering the Australian national phase, the status of the sequence listing depends on what was filed with the international PCT application:
If an ST.26 sequence listing was filed with the PCT application: The international sequence listing automatically forms part of the Australian national phase application. No new sequence listing needs to be filed unless amendments are required.
If an ST.25 sequence listing was filed with the PCT application before 1 July 2022: IP Australia’s transitional provisions allow the ST.25 listing to remain in force for the Australian national phase. However, if amendments to the sequence listing are required during Australian examination, those amendments must be made in ST.26 format – creating a requirement for ST.25 to ST.26 conversion at the point of amendment.
If no sequence listing was filed with the PCT application: If the international application was filed without a sequence listing (an omission that itself generates international phase deficiencies), the applicant must file a compliant ST.26 sequence listing with IP Australia at national phase entry or within the time period specified in any deficiency notice issued by IP Australia.
Language Requirements
Australia’s working language for patents is English. If the PCT international application was filed in a language other than English, an English translation of the specification – and of all sequence listing free text qualifiers – must be provided. The XML structural elements of the ST.26 sequence listing use controlled vocabulary that is defined in English in the standard, but free text /note and /product qualifiers must be in English for Australian national phase filings.
Amendment of Sequence Listings in Australian Applications
When Amendments Are Required
Sequence listing amendments in Australian patent applications may be required:
- In response to an examination report identifying errors, omissions, or inconsistencies in the sequence listing
- When the specification is amended to add or modify sequence-related disclosure (subject to new matter restrictions)
- To correct clerical or formal errors in the listing that do not constitute new matter
- To convert an ST.25 listing to ST.26 format where required by transitional provisions
Procedural Requirements for Amendments
To amend a sequence listing in an Australian application:
- Prepare a corrected or replacement ST.26 XML file using WIPO Sequence
- Validate the amended file through both WIPO Sequence validation and IP Australia’s checking tools
- Submit the amended listing through eServices with a covering explanation of the amendments made
- Simultaneously file any required amendments to the specification to ensure consistency between the specification text and the amended sequence listing
New Matter Restrictions
The new matter provisions of the Patents Act 1990 apply equally to sequence listing amendments. A sequence listing amendment that introduces biological information not supported by the original disclosure of the application – for example, adding a sequence that was not disclosed in the original specification – cannot be made after filing without risking a new matter objection or loss of the original filing date for the added disclosure.
Sequence corrections that fix transcription errors are generally permissible. Sequence additions that introduce new disclosure are not.
Correcting Errors Without New Matter
If a sequence was correctly described in the original specification but incorrectly entered into the sequence listing – a transcription error – the correction can generally be made without raising new matter concerns, provided the specification clearly supports the correct sequence. This distinction between correction of an error and introduction of new matter is a judgment call that should be confirmed with a qualified Australian patent attorney.
IP Australia Examination of Sequence Listings
Formalities Examination
Upon filing, IP Australia conducts a formalities examination that includes review of the sequence listing for:
- Correct file format (ST.26 XML)
- Presence of required header information
- Consistency between the sequence listing and the application documents (applicant name, title, application number)
- Basic structural validity of the XML file
Formalities deficiencies relating to the sequence listing are communicated in a Formalities Examination Report. Applicants typically have two months (extendable) to respond.
Substantive Examination
During substantive examination, the examiner reviews the sequence listing for:
- Completeness: Every sequence that is 10 or more residues in length and is disclosed in the specification must appear in the sequence listing. An omitted sequence that is disclosed and relied upon in the claims may generate a written description or definiteness objection in addition to a sequence listing deficiency.
- SEQ ID NO consistency: Every SEQ ID NO referenced in the specification and claims must correspond to an entry in the sequence listing. Mismatches – where the specification refers to SEQ ID NO: 5 but the listing only contains four sequences, or where SEQ ID NO: 3 in the listing is a different sequence from what the specification describes – generate examination objections.
- Feature annotation adequacy: IP Australia examiners have become increasingly attentive to feature annotation quality as ST.26 use has matured. Sparse or incomplete annotations – particularly for antibody sequences, synthetic constructs and sequences with modified residues – attract comments during examination.
- Biological accuracy: While IP Australia does not independently verify the biological accuracy of sequences against public databases as a matter of routine, significant inconsistencies between annotated features and the sequence data itself may be identified and questioned.
Divisional Applications and Sequence Listings
When a divisional application is filed in Australia based on a parent application that contains a sequence listing, the sequence listing situation requires careful attention:
- If the divisional claims sequences from the parent’s listing: The same sequence listing can be adopted for the divisional, either by reference to the parent’s listing or by filing the identical listing with the divisional.
- If the divisional claims a subset of sequences from the parent’s listing: A new listing containing only the relevant sequences should be prepared, with SEQ ID NO numbering that may differ from the parent. Critically, the divisional specification must use SEQ ID NOs that correspond to the divisional’s listing – which may require consequential amendments to the specification.
- If the divisional adds new sequence-related disclosure: This is subject to the same new matter restrictions as any other new disclosure in a divisional application. New sequences not supported by the parent’s disclosure cannot be added.
Common Deficiencies and How to Avoid Them
Top Formal Deficiencies
- Missing sequence listing: Filing a biotechnology application without any sequence listing when one is required. Always confirm whether sequences of 10 or more residues are disclosed in the application before filing and prepare the listing concurrently with the specification.
- Wrong format: Submitting an ST.25 plain-text file for a new application filed after 1 July 2022. IP Australia will not accept ST.25 for new filings and will require resubmission in ST.26 format.
- Inconsistent applicant name: The applicant name in the sequence listing header does not exactly match the applicant name on the patent application. Even minor variations – “Ltd” versus “Limited,” “Pty Ltd” versus “Proprietary Limited” – generate formalities deficiencies.
- Inconsistent title: The invention title in the sequence listing does not exactly match the title in the patent application. Copy-paste the title – do not retype it.
- Invalid XML: Submitting an XML file that fails the WIPO Sequence validator. Always run both the in-application and standalone validators before submission.
Top Substantive Deficiencies
- Omitted sequences: Sequences disclosed and relied upon in the claims that do not appear in the listing. Perform a complete audit: for every sequence referenced in the claims or specification with a SEQ ID NO, confirm the sequence exists in the listing with that number and correct composition.
- SEQ ID NO mismatches: The number assigned in the listing does not match the number referenced in the specification. This is most common in applications where sequences were added, removed, or reordered during drafting without corresponding updates to both documents.
- Insufficient feature annotations: Antibody sequences without CDR annotations, synthetic sequences without explanatory /note qualifiers, or CDS features missing the /product qualifier. Review every feature annotation against the specification’s description of that sequence before filing.
- Organism name errors: Using a colloquial or non-standard organism name rather than the WIPO Sequence controlled vocabulary form. Always use the organism lookup function in WIPO Sequence.
- Modified residue omissions: Sequences that contain chemically modified residues or non-standard amino acids that are disclosed in the specification but not annotated in the listing.
Working With Australian Patent Attorneys on Sequence Listings
For sequence listing matters, effective collaboration between the technical preparer and the Australian patent attorney is essential.
What the attorney handles:
- Overall prosecution strategy and filing deadlines
- National phase entry formalities and Australian-specific PCT requirements
- Substantive examination responses involving sequence listing issues
- New matter analysis for proposed listing amendments
- Coordination between sequence listing amendments and specification amendments
What the sequence listing specialist handles:
- ST.26 XML file preparation using WIPO Sequence
- Feature annotation in compliance with ST.26 requirements
- Validation before submission
- SEQ ID NO audit against the specification
- ST.25 to ST.26 conversion for legacy applications
Clear division of responsibility and explicit communication between these roles prevents the most common filing errors – including consistency failures between the listing and the specification that only become apparent when both documents are reviewed together.
Way Forward
IP Australia’s sequence listing requirements are based on the international ST.26 framework but include Australia-specific filing, national phase, and examination requirements. Compliance is straightforward: prepare the sequence listing in WIPO Sequence, validate it, ensure consistency with the specification, and file it correctly through IP Australia’s eServices portal. Getting it right at filing avoids deficiency notices, amendment costs, and prosecution delays, making early compliance far more efficient than post-filing corrections.